BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27821509)

  • 21. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
    Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
    Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
    Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
    Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
    Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
    Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms.
    de Lima Guido LP; Chapman J; Cassidy DP
    Am J Clin Pathol; 2023 Jul; 160(1):41-48. PubMed ID: 36881639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
    Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
    Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in non-Hodgkin lymphoid malignancies.
    Ganapathi KA; Brown LE; Prakash S; Bhargava P
    Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
    Gerhard-Hartmann E; Rosenwald A
    Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
    Hilton LK; Tang J; Ben-Neriah S; Alcaide M; Jiang A; Grande BM; Rushton CK; Boyle M; Meissner B; Scott DW; Morin RD
    Blood; 2019 Oct; 134(18):1528-1532. PubMed ID: 31527075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.
    Khanlari M; Medeiros LJ; Lin P; Xu J; You MJ; Tang G; Yin CC; Wang W; Qiu L; Miranda RN; Bueso-Ramos CE; Li S
    Mod Pathol; 2022 Mar; 35(3):419-426. PubMed ID: 34608246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in pathological understanding of high-grade B cell lymphomas.
    Li S; Lin P; Medeiros LJ
    Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
    Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
    [No Abstract]   [Full Text] [Related]  

  • 39. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
    Krull JE; Wenzl K; Hartert KT; Manske MK; Sarangi V; Maurer MJ; Larson MC; Nowakowski GS; Ansell SM; McPhail E; Habermann TM; Link BK; King RL; Cerhan JR; Novak AJ
    Blood Cancer J; 2020 Nov; 10(11):117. PubMed ID: 33168821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.